Trump administration moves to reclassify cannabis in major shift that could expand research

• Cannabis has been reclassified from Schedule I (drugs with no accepted medical use) to Schedule III (drugs with accepted medical use, like Tylenol with codeine and steroids).
• This change specifically applies to medical-grade cannabis, enabling physicians to treat patients and expanding research into its benefits.
• Medical cannabis companies may be relieved of certain tax burdens they previously faced.
• The reclassification does not legalize recreational cannabis, which remains a state-level issue, pending further review by the DEA and DOJ after a public comment period.

The Trump administration reclassified cannabis from Schedule I to Schedule III under federal law, acknowledging its accepted medical use. This significant shift, while not full legalization, is expected to expand scientific research into medical cannabis, allow physicians to treat patients with medical-grade cannabis, and relieve certain tax burdens for medical cannabis companies.